ALHC
Get informed when a big investor buys or sells
+ FollowOvervalued by 185.6% based on the discounted cash flow analysis.
| Market cap | $4.10 Billion |
|---|---|
| Enterprise Value | $3.40 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 1.05 |
| Outstanding Shares | 205,356,397 |
| P/E Ratio | 201.32 |
|---|---|
| PEG | -89.37 |
| Price to Sales | 1.06 |
| Price to Book Ratio | 21.2 |
| Enterprise Value to Revenue | 0.8 |
| Enterprise Value to EBIT | 95.14 |
| Enterprise Value to Net Income | 171 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 26.39% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 0.05%▼ 101.81% |
|---|---|
| Total Invested | $2.40M▼ 99.93% |
| Investors Holding | 8▼ 295.00% |
No data
Alignment Healthcare is a consumer-centric platform delivering customized health care in the United States to seniors and those who need it most, the chronically ill and frail, through its Medicare Advantage plans. Alignment Healthcare p...
This is the primary committee for Medicare policy and reimbursement. Its members have direct influence over the rates and regulations that drive Alignment's revenue.
Its subcommittees determine the specific funding levels for CMS and HHS, which directly provides the revenue for Alignment's Medicare Advantage plans.
Directly oversees the FDA and general health policy; its legislative actions regarding healthcare delivery and labor costs impact ALHC's clinical partners.
Alignment's entire business model centers on seniors. This committee's investigations into drug pricing and long-term care are directly material to its operations.